Recombinant plasma proteins

研究成果: 雜誌貢獻回顧型文獻

28 引文 (Scopus)

摘要

For almost 50-years, the fractionation of human plasma has been the sole possible source of a wide range of therapeutic proteins-such as coagulation factors, anticoagulants, immunoglobulins, and albumin - essential to the treatment of serious congenital or acquired bleeding or immunological diseases. In the last 20-years, the application of recombinant technologies to mammalian cell cultures has made possible - although with some limitations in productivity, costs, and immunogenic risks - to produce and commercialize complex plasma glycoproteins for human therapeutic applications and has opened the way to the development of new molecular entities. Today, the advanced exploration of alternative cell lines and enhanced cell culture systems, as well as the development of alternative expression technologies, such as transgenic animals, is opening a new era in the production of the full range of recombinant plasma protein therapeutics. In this review, we examine the achievements and ongoing challenges of the recombinant DNA technology as a platform for the production of plasma proteins and the advantages and limitations of such products compared to fractionated plasma proteins.
原文英語
頁(從 - 到)68-83
頁數16
期刊Vox Sanguinis
100
發行號1
DOIs
出版狀態已發佈 - 一月 2011
對外發佈Yes

指紋

Recombinant Proteins
Blood Proteins
Technology
Cell Culture Techniques
Genetically Modified Animals
Blood Coagulation Factors
Recombinant DNA
Immune System Diseases
Anticoagulants
Immunoglobulins
Albumins
Glycoproteins
Therapeutics
Hemorrhage
Efficiency
Costs and Cost Analysis
Cell Line
Proteins

ASJC Scopus subject areas

  • Hematology

引用此文

Recombinant plasma proteins. / Burnouf, T.

於: Vox Sanguinis, 卷 100, 編號 1, 01.2011, p. 68-83.

研究成果: 雜誌貢獻回顧型文獻

Burnouf, T. / Recombinant plasma proteins. 於: Vox Sanguinis. 2011 ; 卷 100, 編號 1. 頁 68-83.
@article{2a320bbc451041b7b51a4617b1cfc9e9,
title = "Recombinant plasma proteins",
abstract = "For almost 50-years, the fractionation of human plasma has been the sole possible source of a wide range of therapeutic proteins-such as coagulation factors, anticoagulants, immunoglobulins, and albumin - essential to the treatment of serious congenital or acquired bleeding or immunological diseases. In the last 20-years, the application of recombinant technologies to mammalian cell cultures has made possible - although with some limitations in productivity, costs, and immunogenic risks - to produce and commercialize complex plasma glycoproteins for human therapeutic applications and has opened the way to the development of new molecular entities. Today, the advanced exploration of alternative cell lines and enhanced cell culture systems, as well as the development of alternative expression technologies, such as transgenic animals, is opening a new era in the production of the full range of recombinant plasma protein therapeutics. In this review, we examine the achievements and ongoing challenges of the recombinant DNA technology as a platform for the production of plasma proteins and the advantages and limitations of such products compared to fractionated plasma proteins.",
keywords = "Plasma, Proteins, Recombinant",
author = "T. Burnouf",
year = "2011",
month = "1",
doi = "10.1111/j.1423-0410.2010.01384.x",
language = "English",
volume = "100",
pages = "68--83",
journal = "Vox Sanguinis",
issn = "0042-9007",
publisher = "Blackwell Publishing Ltd",
number = "1",

}

TY - JOUR

T1 - Recombinant plasma proteins

AU - Burnouf, T.

PY - 2011/1

Y1 - 2011/1

N2 - For almost 50-years, the fractionation of human plasma has been the sole possible source of a wide range of therapeutic proteins-such as coagulation factors, anticoagulants, immunoglobulins, and albumin - essential to the treatment of serious congenital or acquired bleeding or immunological diseases. In the last 20-years, the application of recombinant technologies to mammalian cell cultures has made possible - although with some limitations in productivity, costs, and immunogenic risks - to produce and commercialize complex plasma glycoproteins for human therapeutic applications and has opened the way to the development of new molecular entities. Today, the advanced exploration of alternative cell lines and enhanced cell culture systems, as well as the development of alternative expression technologies, such as transgenic animals, is opening a new era in the production of the full range of recombinant plasma protein therapeutics. In this review, we examine the achievements and ongoing challenges of the recombinant DNA technology as a platform for the production of plasma proteins and the advantages and limitations of such products compared to fractionated plasma proteins.

AB - For almost 50-years, the fractionation of human plasma has been the sole possible source of a wide range of therapeutic proteins-such as coagulation factors, anticoagulants, immunoglobulins, and albumin - essential to the treatment of serious congenital or acquired bleeding or immunological diseases. In the last 20-years, the application of recombinant technologies to mammalian cell cultures has made possible - although with some limitations in productivity, costs, and immunogenic risks - to produce and commercialize complex plasma glycoproteins for human therapeutic applications and has opened the way to the development of new molecular entities. Today, the advanced exploration of alternative cell lines and enhanced cell culture systems, as well as the development of alternative expression technologies, such as transgenic animals, is opening a new era in the production of the full range of recombinant plasma protein therapeutics. In this review, we examine the achievements and ongoing challenges of the recombinant DNA technology as a platform for the production of plasma proteins and the advantages and limitations of such products compared to fractionated plasma proteins.

KW - Plasma

KW - Proteins

KW - Recombinant

UR - http://www.scopus.com/inward/record.url?scp=78650355088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650355088&partnerID=8YFLogxK

U2 - 10.1111/j.1423-0410.2010.01384.x

DO - 10.1111/j.1423-0410.2010.01384.x

M3 - Review article

C2 - 21175657

AN - SCOPUS:78650355088

VL - 100

SP - 68

EP - 83

JO - Vox Sanguinis

JF - Vox Sanguinis

SN - 0042-9007

IS - 1

ER -